Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 EBITDA Margin % is 13.33% as of Dec. 2025, which is 0% below its 10-year median of 13.34. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, CF PharmTech ranks better than 52.82% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CF PharmTech's EBITDA for the
six
months ended in Dec. 2025 was HK$63.7 Mil. CF PharmTech's Revenue for the
six
months ended in Dec. 2025 was HK$477.8 Mil. Therefore, CF PharmTech's EBITDA margin for the quarter that ended in Dec. 2025 was 13.33%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CF PharmTech EBITDA Margin % Related Terms
CF PharmTech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CF PharmTech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech EBITDA Margin % Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
EBITDA Margin %
-9.04
13.80
13.35
13.33
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
EBITDA Margin %
-9.04
13.80
13.35
13.33
HKSE:02652 vs ZTS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CF PharmTech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech (HKSE:02652) has a EBITDA Margin % of 13.33% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CF PharmTech and its competitors. This is near median its historical median of 13.34. According to the industry distribution chart, CF PharmTech ranks #452 out of 958 companies in the Drug Manufacturers industry, placing it in the top 47.2%.
Is CF PharmTech's EBITDA Margin % too high?
CF PharmTech's current EBITDA Margin % of 13.33% is near median its 10-year median of 13.34. The Drug Manufacturers industry median EBITDA Margin % is 12.11. CF PharmTech's value of 13.33% is 10.1% above this industry median. Based on the distribution chart, CF PharmTech ranks #452 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #452 out of 958 companies for EBITDA Margin %. This puts CF PharmTech in the upper half of its industry. The industry median EBITDA Margin % is 12.11. CF PharmTech's value of 13.33% is 10.1% above this benchmark. While the company's 10-year median is 13.34 vs. the industry median of 12.11, CF PharmTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CF PharmTech's current EBITDA Margin % of 13.33% is 10.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current EBITDA Margin % is 13.33%, which is near median its own 10-year median of 13.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current EBITDA Margin % of 13.33%. The current EBITDA Margin % is 13.33%, which is near median its 10-year median of 13.34 and 10.1% above the Drug Manufacturers industry median of 12.11. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current EBITDA Margin % is 13.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
